


## L-364,373

<b>Cat. No.:</b>	HY-108591		
<b>CAS No.:</b>	103342-82-1		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>20</sub> FN <sub>3</sub> O		
<b>Molecular Weight:</b>	397.44		
<b>Target:</b>	Potassium Channel		
<b>Pathway:</b>	Membrane Transporter/Ion Channel		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (251.61 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.5161 mL	12.5805 mL	25.1610 mL
5 mM	0.5032 mL	2.5161 mL	5.0322 mL
10 mM	0.2516 mL	1.2581 mL	2.5161 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: 2.5 mg/mL (6.29 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: 2.5 mg/mL (6.29 mM); Clear solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates I<sub>ks</sub> (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes<sup>[1]</sup>.

### REFERENCES

- [1]. Jow F, et al. Rb<sup>+</sup> efflux through functional activation of cardiac KCNQ1/minK channels by the benzodiazepine R-L3 (L-364,373). *Assay Drug Dev Technol.* 2006 Aug;4(4):443-50.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA